2DAP 092
Latest Information Update: 30 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antifungals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 23 Jan 1998 Preclinical development for Mycoses in Italy (Unknown route)
- 23 Jan 1998 Preclinical development for Mycoses in USA (Unknown route)